The dopaminergic system in hypertension

Zeng, Chunyu; Zhang, Meng; Asico, Laureano D.; Eisner, Gilbert M.; José, Pedro A.

doi:10.1042/cs20070018

Cited by 110 publications

(110 citation statements)

References 171 publications

(378 reference statements)

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…At low concentrations, dopamine activates D1 and D2 receptors and dilates interlobular arteries and both the afferent and efferent arterioles, resulting in an increased renal blood flow and a marked natriuretic response. At high concentrations, however, dopamine induces renal vasoconstriction via activation of the ␣-adrenergic receptors (22,29). We previously demonstrated that dopamine is a preferred physiological substrate of PMAT (5).…”

Section: Discussionmentioning

confidence: 99%

“…Dopamine is synthesized in the proximal tubule and is released as a paracrine and autocrine hormone to act on different receptors in the renal tubules, glomeruli, and renal blood vessels (2,29). Dopamine exerts profound effects on renal hemodynamics in a dosedependant manner (22,29). At low concentrations, dopamine activates D1 and D2 receptors and dilates interlobular arteries and both the afferent and efferent arterioles, resulting in an increased renal blood flow and a marked natriuretic response.…”

Section: Discussionmentioning

confidence: 99%

“…It is well-recognized that the catecholamine dopamine plays important roles in blood pressure regulation by modulating renal blood flow, glomerular filtration rate, and epithelial sodium transport (22,29). Dopamine is synthesized in the proximal tubule and is released as a paracrine and autocrine hormone to act on different receptors in the renal tubules, glomeruli, and renal blood vessels (2,29).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Podocyte-specific expression of organic cation transporter PMAT: implication in puromycin aminonucleoside nephrotoxicity

Li¹,

Zhou²,

Kalhorn³

et al. 2009

American Journal of Physiology-Renal Physiology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Podocyte-specific expression of organic cation transporter PMAT: implication in puromycin aminonucleoside nephrotoxicity

Li¹,

Zhou²,

Kalhorn³

et al. 2009

American Journal of Physiology-Renal Physiology

View full text Add to dashboard Cite

show abstract

“…DA has been shown to regulate behavior, movement, and cardiovascular, renal, endocrine, gastrointestinal, and immune functions (8)(9)(10). Normal blood vessels are supplied by sympathetic nerves, and neurotransmitters released from these nerve endings regulate many critical vascular functions (8,(11)(12)(13)(14)(15). Because DA is one of the catecholamine neurotransmitters in the sympathetic nerve endings and regulates important vascular functions such as vessel tone and blood pressure by acting through its receptors present in blood vessels (8,9,(13)(14)(15)(16)(17)(18)(19)(20), we investigated whether DA has other effects on abnormal tumor blood vessels.…”

mentioning

confidence: 99%

Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Krüppel-like factor-2 expression in tumor endothelial cells

Chakroborty

Sarkar

et al. 2011

Proc. Natl. Acad. Sci. U.S.A.

101

View full text Add to dashboard Cite

Impaired blood flow in the tumor vascular bed caused by structurally and functionally abnormal blood vessels not only hinders the delivery of chemotherapeutic agents but also aggravates tumor hypoxia, making the tumor cells further resistant to antineoplastic drugs. Therefore, normalization of tumor blood vessels may be an important approach to increase therapeutic efficacy in the treatment of cancer patients. As blood vessels are supplied by sympathetic nerves containing dopamine (DA), and DA regulates functions of normal blood vessels through its receptors present in these vessels, we investigated the effect of DA on tumor vasculature. Here we report loss of sympathetic innervation and endogenous DA in abnormal and immature tumor blood vessels in malignant colon and prostate tumor tissues. In contrast, exogenous administration of DA normalizes the morphology and improves the functions of these vessels by acting on pericytes and endothelial cells, the two major cellular components of blood vessels. DA acts through its D 2 receptors present in these cells to up-regulate directly the expression of angiopoietin 1 (Ang1) in pericytes and the expression of the zinc finger transcriptional factor, Krüppel-like factor-2 (KLF2) in tumor endothelial cells. Importantly, this vessel stabilization by DA also significantly increases the concentration of anticancer drug in tumor tissues. These results show a relationship between vascular stabilization and a neurotransmitter and indicate that DA or its D 2 receptor-specific agonists can be an option for the treatment of cancer and disorders in which normalization of blood vessels may have therapeutic benefits.I t now is well established that tumor blood vessels are structurally and functionally abnormal (1-4). In contrast to normal blood vessels, which are well organized and lined by quiescent adult endothelial cells and supporting mature pericytes, tumor vessels are highly disorganized and made up of active endothelial cells (1-6). Moreover, in these tumor vessels pericytes are lacking or immature pericytes attach loosely to the endothelial cells (1-3). This vascular immaturity in turn causes destabilization of vessel structure, impairment of endothelial barrier function, and decreased blood flow leading to increased hypoxia in tumor tissues (1-3). In addition, the impaired blood flow in abnormal tumor blood vessels not only compromises the delivery of anticancer drugs but also aggravates tumor hypoxia, making tumor cells more resistant to these agents (1-3). Thus, stabilization or normalization of tumor vessels can be an important approach to increase the therapeutic efficacy of anticancer drugs (1, 7). Dopamine (DA) is a monoamine catecholamine neurotransmitter, which acts through its D 1 and D 2 class of receptors present in the target organs (8, 9). In addition to its conventional role in the brain, recent reports indicate that DA also controls several functions in the periphery (8, 9). DA has been shown to regulate behavior, movement, and cardiovascular, renal, endocrine...

show abstract

“…behavioural syndromes, sedative effects) or peripheral, some of which affect the cardiovascular system [2]. Cardiovascular effects of DAs are thought to be related to the activation of dopaminergic and non-dopaminergic receptors [17,18]. D1-like and D2-like dopamine receptors located at various sites within the vascular, cardiac and renal regions have been shown to mediate cardiovascular and renal effects [19].…”

Section: Discussionmentioning

confidence: 99%

A Prospective, Multicenter, 2-Year Echocardiographic Study on Valvular Heart Disease in Parkinson's Disease Patients Taking Rotigotine and Other non-Ergot Dopamine Agonists

Eggert¹,

Antony²

2016

J Alzheimers Dis Parkinsonism

View full text Add to dashboard Cite

Objectives: We explored the possible risk of valvular heart disease (VHD) in Parkinson's disease (PD) patients taking rotigotine compared to other non-ergot dopamine agonists (DA) as requested by the EMA (European Medicines Agency) in terms of assessing the longterm safety associated with the cumulative dose of rotigotine. Methods:We performed a prospective, multicenter, open-label, 2-year echocardiographic study in PD patients taking rotigotine or other non-ergot DA (piribedil, pramipexole, ropinirole). Valvular pathology was assessed by transthoracic echocardiographic examinations according to American Society of Echocardiography recommendations and a scoring system for restrictive VHD at 1-month, 12-months and 24-months follow-up examination. Routine neurological and physical examinations with special attention toward clinical symptoms of heart failure were performed after 1, 6, 12, 18 and 24 months.Results: 102 out of 107 screened patients were enrolled into the study. Due to drop-outs along the 2-year followup, 66 patients (28 rotigotine, 38 other non-ergot DAs [3 piribedil, 20 pramipexole, 15 ropinirole]) completed the 12-months visit and 53 patients (23 rotigotine, 30 other non-ergot DAs [3 piribedil, 16 pramipexole, 11 ropinirole]) completed the 24-months visit. No patient showed clinical symptoms of heart failure or echocardiographic evidence of restrictive VHD during the 2-year period. Analyses of valve regurgitation (VR) revealed no case of severe or moderate VR in the rotigotine group. Only one patient taking pramipexole showed moderate VR at 1-month and 12-months follow-up visit decreasing to mild degree at 24-months follow-up.Conclusions: This is the first prospective study assessing the possible risk of VHD in patients taking rotigotine. We did not find valvular pathology suggestive for restrictive VHD or increased risk of cardiac VR in PD patients receiving rotigotine or other non-ergot DAs. Future studies are needed to explore the clinical relevance and the relationship between non-ergot DAs and heart failure including effects of cumulative dose or comedication with other antiparkinsonian drugs.

show abstract

The dopaminergic system in hypertension

Cited by 110 publications

References 171 publications

Podocyte-specific expression of organic cation transporter PMAT: implication in puromycin aminonucleoside nephrotoxicity

Podocyte-specific expression of organic cation transporter PMAT: implication in puromycin aminonucleoside nephrotoxicity

Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Krüppel-like factor-2 expression in tumor endothelial cells

A Prospective, Multicenter, 2-Year Echocardiographic Study on Valvular Heart Disease in Parkinson's Disease Patients Taking Rotigotine and Other non-Ergot Dopamine Agonists

Contact Info

Product

Resources

About